Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Pharmacological Assays for Investigating the NOP Receptor.

Malfacini D, Calo' G.

Handb Exp Pharmacol. 2019 Feb 7. doi: 10.1007/164_2018_200. [Epub ahead of print]

PMID:
30725284
2.

NOP-Targeted Peptide Ligands.

Preti D, Calo' G, Guerrini R.

Handb Exp Pharmacol. 2019 Jan 29. doi: 10.1007/164_2018_198. [Epub ahead of print]

PMID:
30689091
3.

NOP receptor pharmacological profile - A dynamic mass redistribution study.

Malfacini D, Simon K, Trapella C, Guerrini R, Zaveri NT, Kostenis E, Calo' G.

PLoS One. 2018 Aug 30;13(8):e0203021. doi: 10.1371/journal.pone.0203021. eCollection 2018.

4.

NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Holanda VAD, Santos WB, Asth L, Guerrini R, Calo' G, Ruzza C, Gavioli EC.

Psychopharmacology (Berl). 2018 Nov;235(11):3093-3102. doi: 10.1007/s00213-018-5004-7. Epub 2018 Aug 25.

PMID:
30145654
5.

Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.

Silva EF, Silva AI, Asth L, Souza LS, Zaveri NT, Guerrini R, Calo' G, Ruzza C, Gavioli EC.

Behav Brain Res. 2019 Jan 1;356:120-126. doi: 10.1016/j.bbr.2018.08.019. Epub 2018 Aug 22.

PMID:
30142397
6.

In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2, a mu opioid receptor agonist biased toward β-arrestin.

Gach-Janczak K, Piekielna-Ciesielska J, Adamska-Bartłomiejczyk A, Wtorek K, Ferrari F, Calo' G, Szymaszkiewicz A, Piasecka-Zelga J, Janecka A.

Peptides. 2018 Jul;105:51-57. doi: 10.1016/j.peptides.2018.04.014. Epub 2018 Apr 22.

PMID:
29684591
7.

Cyclopeptide Dmt-[D-Lys-p-CF3-Phe-Phe-Asp]NH2, a novel G protein-biased agonist of the mu opioid receptor.

Piekielna-Ciesielska J, Ferrari F, Calo' G, Janecka A.

Peptides. 2018 Mar;101:227-233. doi: 10.1016/j.peptides.2017.11.020. Epub 2017 Nov 28.

PMID:
29196181
8.

Peptide welding technology - A simple strategy for generating innovative ligands for G protein coupled receptors.

Calo' G, Rizzi A, Ruzza C, Ferrari F, Pacifico S, Gavioli EC, Salvadori S, Guerrini R.

Peptides. 2018 Jan;99:195-204. doi: 10.1016/j.peptides.2017.10.004. Epub 2017 Oct 13. Review.

PMID:
29031796
9.

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT.

Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.333.

10.

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.

Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L.

Neuropharmacology. 2017 Oct;125:39-49. doi: 10.1016/j.neuropharm.2017.07.006. Epub 2017 Jul 10.

PMID:
28705439
11.

Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test.

Rizzi A, Ruzza C, Bianco S, Trapella C, Calo' G.

Peptides. 2017 Aug;94:71-77. doi: 10.1016/j.peptides.2017.07.002. Epub 2017 Jul 8.

PMID:
28697954
12.

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.

Rizzi A, Cerlesi MC, Ruzza C, Malfacini D, Ferrari F, Bianco S, Costa T, Guerrini R, Trapella C, Calo' G.

Pharmacol Res Perspect. 2016 Aug 2;4(4):e00247. doi: 10.1002/prp2.247. eCollection 2016 Aug.

13.

Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Holanda VA, Medeiros IU, Asth L, Guerrini R, Calo' G, Gavioli EC.

Psychopharmacology (Berl). 2016 Jul;233(13):2525-32. doi: 10.1007/s00213-016-4310-1. Epub 2016 Apr 30.

PMID:
27129865
14.

Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.

Piekielna J, De Marco R, Gentilucci L, Cerlesi MC, Calo' G, Tömböly C, Artali R, Janecka A.

Biopolymers. 2016 May;106(3):309-17. doi: 10.1002/bip.22846.

PMID:
27038094
15.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

16.

Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.

Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G.

Neuropharmacology. 2016 Jun;105:434-442. doi: 10.1016/j.neuropharm.2016.02.003. Epub 2016 Feb 8.

17.

Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.

Malfacini D, Ambrosio C, Gro' MC, Sbraccia M, Trapella C, Guerrini R, Bonora M, Pinton P, Costa T, Calo' G.

PLoS One. 2015 Aug 6;10(8):e0132865. doi: 10.1371/journal.pone.0132865. eCollection 2015.

18.

Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity.

Piekielna J, Kluczyk A, Gentilucci L, Cerlesi MC, Calo' G, Tomböly C, Łapiński K, Janecki T, Janecka A.

Org Biomol Chem. 2015 Jun 7;13(21):6039-46. doi: 10.1039/c5ob00565e.

PMID:
25948019
19.

In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant.

Ruzza C, Rizzi A, Malfacini D, Molinari S, Giuliano C, Lovati E, Pietra C, Calo' G.

Peptides. 2015 Jul;69:26-32. doi: 10.1016/j.peptides.2015.03.021. Epub 2015 Apr 3.

PMID:
25843024
20.

Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test.

Holanda AD, Asth L, Santos AR, Guerrini R, de P Soares-Rachetti V, Calo' G, André E, Gavioli EC.

Life Sci. 2015 Jan 1;120:8-12. doi: 10.1016/j.lfs.2014.10.021. Epub 2014 Nov 12.

21.

Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task.

Asth L, Correia N, Lobão-Soares B, De Lima TC, Guerrini R, Calo' G, Soares-Rachetti VP, Gavioli EC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):33-41. doi: 10.1007/s00210-014-1055-4. Epub 2014 Oct 16.

PMID:
25319847
22.

A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ.

Guerrini R, Marzola E, Trapella C, Pela' M, Molinari S, Cerlesi MC, Malfacini D, Rizzi A, Salvadori S, Calo' G.

Bioorg Med Chem. 2014 Jul 15;22(14):3703-12. doi: 10.1016/j.bmc.2014.05.005. Epub 2014 May 13.

PMID:
24878361
23.

Pharmacological characterization of endomorphin-2-based cyclic pentapeptides with methylated phenylalanine residues.

Perlikowska R, Malfacini D, Cerlesi MC, Calo' G, Piekielna J, Floriot L, Henry T, do-Rego JC, Tömböly C, Kluczyk A, Janecka A.

Peptides. 2014 May;55:145-50. doi: 10.1016/j.peptides.2014.03.001. Epub 2014 Mar 13.

PMID:
24632335
24.

Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.

Didonet JJ, Cavalcante JC, Souza Lde S, Costa MS, André E, Soares-Rachetti Vde P, Guerrini R, Calo' G, Gavioli EC.

Behav Brain Res. 2014 Jun 1;266:29-36. doi: 10.1016/j.bbr.2014.03.002. Epub 2014 Mar 11.

PMID:
24613977
25.

Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.

Gavioli EC, Calo' G.

Pharmacol Ther. 2013 Oct;140(1):10-25. doi: 10.1016/j.pharmthera.2013.05.008. Epub 2013 May 24. Review.

PMID:
23711793
26.

Chimeric G proteins in fluorimetric calcium assays: experience with opioid receptors.

Camarda V, Calo' G.

Methods Mol Biol. 2013;937:293-306.

PMID:
23007594
27.

Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice.

Ramos SF, Mendonça BP, Leffa DD, Pacheco R, Damiani AP, Hainzenreder G, Petronilho F, Dal-Pizzol F, Guerrini R, Calo' G, Gavioli EC, Boeck CR, de Andrade VM.

Pharmacol Biochem Behav. 2012 Dec;103(2):197-203. doi: 10.1016/j.pbb.2012.09.001. Epub 2012 Sep 7.

28.

[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Molinari S, Camarda V, Rizzi A, Marzola G, Salvadori S, Marzola E, Molinari P, McDonald J, Ko MC, Lambert DG, Calo' G, Guerrini R.

Br J Pharmacol. 2013 Jan;168(1):151-62. doi: 10.1111/j.1476-5381.2012.02115.x.

29.

In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.

Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo' G.

Peptides. 2012 Sep;37(1):86-97. doi: 10.1016/j.peptides.2012.06.010. Epub 2012 Jun 23.

PMID:
22732666
30.

[tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies.

Ruzza C, Rizzi A, Camarda V, Pulga A, Marzola G, Filaferro M, Novi C, Ruggieri V, Marzola E, Vitale G, Salvadori S, Guerrini R, Calo' G.

Peptides. 2012 Apr;34(2):404-11. doi: 10.1016/j.peptides.2012.01.024. Epub 2012 Feb 9.

PMID:
22342393
31.

Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor.

Ruzza C, Pulga A, Rizzi A, Marzola G, Guerrini R, Calo' G.

Neuropharmacology. 2012 Apr;62(5-6):1999-2009. doi: 10.1016/j.neuropharm.2011.12.036. Epub 2012 Jan 10.

PMID:
22248636
32.

Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice.

Pacheco R, Pescador BB, Mendonça BP, Ramos SF, Guerrini R, Calo' G, de Andrade VM, Gavioli EC, Boeck CR.

Pharmacol Biochem Behav. 2011 Oct;99(4):726-30. doi: 10.1016/j.pbb.2011.06.028. Epub 2011 Jul 1.

33.

Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies.

Rizzi A, Molinari S, Marti M, Marzola G, Calo' G.

Neuropharmacology. 2011 Mar;60(4):572-9. doi: 10.1016/j.neuropharm.2010.12.010. Epub 2010 Dec 22.

PMID:
21184763
34.

UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Calo' G, Rizzi A, Cifani C, Micioni Di Bonaventura MV, Regoli D, Massi M, Salvadori S, Lambert DG, Guerrini R.

CNS Neurosci Ther. 2011 Jun;17(3):178-98. doi: 10.1111/j.1755-5949.2009.00107.x. Epub 2010 May 18. Review.

PMID:
20497197
35.

Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68.

Ruzza C, Rizzi A, Trapella C, Pela' M, Camarda V, Ruggieri V, Filaferro M, Cifani C, Reinscheid RK, Vitale G, Ciccocioppo R, Salvadori S, Guerrini R, Calo' G.

Peptides. 2010 May;31(5):915-25. doi: 10.1016/j.peptides.2010.02.012. Epub 2010 Feb 19.

PMID:
20172007
36.

Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice.

Boeck CR, Martinello C, de Castro AA, Moretti M, Dos Santos Casagrande T, Guerrini R, Calo' G, Gavioli EC.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):153-60. doi: 10.1007/s00210-009-0480-2. Epub 2009 Dec 19.

PMID:
20020280
37.

Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.

Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo' G.

Med Res Rev. 2010 Sep;30(5):751-77. doi: 10.1002/med.20180. Review.

PMID:
19824051
38.

Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.

Bojnik E, Babos F, Fischetti C, Magyar A, Camarda V, Borsodi A, Bajusz S, Calo' G, Benyhe S.

Brain Res Bull. 2010 Mar 16;81(4-5):477-83. doi: 10.1016/j.brainresbull.2009.09.013. Epub 2009 Oct 2.

PMID:
19800951
39.

Lithium attenuates behavioral and biochemical effects of neuropeptide S in mice.

Castro AA, Casagrande TS, Moretti M, Constantino L, Petronilho F, Guerra GC, Calo' G, Guerrini R, Dal-Pizzol F, Quevedo J, Gavioli EC.

Peptides. 2009 Oct;30(10):1914-20. doi: 10.1016/j.peptides.2009.07.004. Epub 2009 Jul 16.

PMID:
19616051
40.

Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.

Trapella C, Fischetti C, Pela' M, Lazzari I, Guerrini R, Calo' G, Rizzi A, Camarda V, Lambert DG, McDonald J, Regoli D, Salvadori S.

Bioorg Med Chem. 2009 Jul 15;17(14):5080-95. doi: 10.1016/j.bmc.2009.05.068. Epub 2009 Jun 2.

PMID:
19527931
41.

Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.

Batuwangala M, Camarda V, McDonald J, Marzola E, Lambert DG, Ng LL, Calo' G, Regoli D, Trapella C, Guerrini R, Salvadori S.

Peptides. 2009 Jun;30(6):1130-6. doi: 10.1016/j.peptides.2009.02.003. Epub 2009 Feb 12.

PMID:
19463746
42.

Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.

Fischetti C, Camarda V, Rizzi A, Pelà M, Trapella C, Guerrini R, McDonald J, Lambert DG, Salvadori S, Regoli D, Calo' G.

Eur J Pharmacol. 2009 Jul 1;614(1-3):50-7. doi: 10.1016/j.ejphar.2009.04.054. Epub 2009 May 12.

PMID:
19445927
43.

Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam.

Castro AA, Moretti M, Casagrande TS, Martinello C, Petronilho F, Steckert AV, Guerrini R, Calo' G, Dal Pizzol F, Quevedo J, Gavioli EC.

Pharmacol Biochem Behav. 2009 Feb;91(4):636-42. doi: 10.1016/j.pbb.2008.10.015. Epub 2008 Oct 31.

PMID:
19022279
44.

Structure-activity study at positions 3 and 4 of human neuropeptide S.

Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S.

Bioorg Med Chem. 2008 Oct 1;16(19):8841-5. doi: 10.1016/j.bmc.2008.08.073. Epub 2008 Aug 31.

PMID:
18793857
45.

Urotensin II evokes neurotransmitter release from rat cerebrocortical slices.

Ono T, Kawaguchi Y, Kudo M, Kushikata T, Hashiba E, Yoshida H, Kudo T, Furukawa K, Douglas SA, Guerrini R, Calo' G, Hirota K.

Neurosci Lett. 2008 Aug 8;440(3):275-9. doi: 10.1016/j.neulet.2008.05.096. Epub 2008 Jun 21.

PMID:
18572318
46.

Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices.

Kuo CJ, Liao YY, Guerrini R, Calo' G, Chiou LC.

Eur J Pharmacol. 2008 Jan 28;579(1-3):110-5. Epub 2007 Oct 11.

PMID:
17976580
47.

Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11).

Marzola E, Camarda V, Batuwangala M, Lambert DG, Calo' G, Guerrini R, Trapella C, Regoli D, Tomatis R, Salvadori S.

Peptides. 2008 May;29(5):674-9. Epub 2007 Jul 31.

PMID:
17822806
48.

In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).

Kitayama M, McDonald J, Barnes TA, Calo' G, Guerrini R, Rowbotham DJ, Lambert DG.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Aug;375(6):369-76. Epub 2007 Jun 28.

PMID:
17598088
49.

Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.

Gavioli EC, Rizzi A, Marzola G, Zucchini S, Regoli D, Calo' G.

Peptides. 2007 Jun;28(6):1229-39. Epub 2007 Apr 27.

PMID:
17499882
50.

Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies.

Vergura R, Valenti E, Hebbes CP, Gavioli EC, Spagnolo B, McDonald J, Lambert DG, Balboni G, Salvadori S, Regoli D, Calo' G.

Peptides. 2006 Dec;27(12):3322-30. Epub 2006 Sep 11.

PMID:
16963157

Supplemental Content

Support Center